|TDB VacciGrade™||Unit size||Cat. code||Docs||Qty||Price|
Vaccine Adjuvant - Mincle agonist
Mincle agonist - Synthetic analog of the cord factor
Trehalose-6,6-dibehenate (TDB) is a non-toxic synthetic analogue of the mycobacterial cell wall component trehalose 6,6’ dimycolate (TDM, also known as cord factor).
TDB was shown to rely on the C-type lectin Mincle and the signaling molecules Syk and Card9 to trigger innate immunity.
TDB VacciGrade™ is suitable for preclinical studies. It is prepared under strict aseptic conditions. It is guaranteed sterile and thoroughly tested for the presence of endotoxins.
TDB VacciGrade™ is for research use only, not for use in humans.Back to the top
Specificity: Th1 response.
Quality: Sterile, Endotoxin level < 5 EU/mg.
CAS number: 66758-35-8.
Molecular weight: 987.43.
Working concentration: 1 - 100 µg/mouse.
- TDB VacciGrade™ is a preclinical grade.
- It is prepared under strict aseptic conditions and is tested for the presence of endotoxins.
- TDB VacciGrade™ is guaranteed sterile and its endotoxin level is <5 EU/mg.
TDB VacciGrade™ is provided as a sterile powder.
- 2 x 1 mg TDB VacciGrade™
- 10 ml sterile endotoxin-free physiological water (NaCl 0.9%)
TDB VacciGrade™ is shipped at room temperature.
Store at -20°C.
Lyophilized product is stable for 1 year at -20°C.Back to the top
Chemical structure of TDB:
Trehalose-6,6-dibehenate (TDB) is a non-toxic synthetic analog of the mycobacterial cell wall component trehalose 6,6’ dimycolate (TDM, also known as cord factor).
TDB was shown to rely on the C-type lectin Mincle and the signaling molecules Syk and Card9 to trigger innate immunity . Incorporation of TDB combined with the synthetic amphiphilic cationic lipid compound dimethyldioctadecylammonium (DDA) into liposomes, known as CAF01, has been shown to strongly enhance cellular and humoral responses against a protein antigen . Adjuvanticity of the cationic DDA:TDB liposomes and sustained protection against disease challenge has been demonstrated in particular with a tuberculosis vaccine candidate [3, 4], and has good potential for application in a range of other diseases .
1. Schoenen H, et al., 2010. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J Immunol. ;184(6):2756-60.
2. Davidsen J, et al., 2005. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim Biophys Acta. 1718(1-2):22-31.
3. Holten-Andersen L. et al., 2004. Combination of the cationic surfactant dimethyl dioctadecyl ammonium bromide and synthetic mycobacterial cord factor as an efficient adjuvant for tuberculosis subunit vaccines. Infect Immun. 72(3):1608-17.
4. Christensen D. et al., 2011. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines. 10(4):513-21.
5. Agger EM. et al., 2008. Cationic liposomes formulated with synthetic mycobacterial cord factor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 3(9):e3116.